Gil M. Labrucherie Purchases 6,282 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 6,282 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was acquired at an average price of $5.59 per share, with a total value of $35,116.38. Following the purchase, the chief financial officer now directly owns 36,282 shares in the company, valued at $202,816.38. This represents a 20.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Septerna Trading Up 1.8 %

Septerna stock traded up $0.10 during midday trading on Thursday, reaching $5.80. 265,272 shares of the stock traded hands, compared to its average volume of 571,590. The business’s fifty day moving average price is $16.78. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $43.00 to $14.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. TD Cowen started coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Tower Research Capital LLC TRC bought a new position in Septerna during the fourth quarter valued at $25,000. New York State Common Retirement Fund purchased a new position in Septerna in the fourth quarter worth about $32,000. Legal & General Group Plc bought a new stake in Septerna during the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. purchased a new stake in Septerna during the fourth quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in Septerna during the fourth quarter valued at approximately $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.